PDUFA action date for Hansa Biopharma’s imlifidase BLA set for December 19, 2026 Hansa Biopharma announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. đź“şOptimum TV […]
Novo Nordisk Foundation announced it had awarded DKK 11.8 billion (€1.6 billion) during 2025 to support more than 2,200 projects aimed at improving people’s health and the sustainability of society and the planet. The projects cover the full range of the Foundation’s grant-giving areas, including key topics such as cardiometabolic diseases, antimicrobial resistance, the development of more resilient and climate-friendly […]
European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem The European Life Sciences Coalition (ELSC)  launched this week to strengthen Europe’s life sciences and biotechnology VC ecosystem by mobilising greater levels of private and public investment across the sector. Created in association with Invest Europe, the coalition brings together leading European life […]
Biocomposites launches SYNICEM™ spacers in Canada Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, has launched its SYNICEM™ hip, knee and shoulder preformed spacers in Canada. It follows the launch of the same products in the US last October. Biocomposites, […]
As one of the organisers, Optimum is proud to partner with Anglonordic year on year to curate an awesome agenda for this fantastic event. Exclusively for European investors and R&D companies…
